Shots: The P-III study will evaluate Ultomiris vs BSC in 270 patients in a ratio (2:1) hospitalized with COVID-19 and severe pneumonia, acute lung injury or ARDS. In the study, […]readmore
Tags : ravulizumab-cwvz
Shots: The P-III study involves assessing of Ultomiris (IV) in complement inhibitor-naïve patients with aHUS, receiving dose based on their weight varying upto 3,600 mg for 2 years P-III study […]readmore
Biosimilars
Regulatory
Alexion’s Ultomiris (Ravulizumab-Cwvz) Receives FDA Approval in Patients with Paroxysmal
Shots: The approval is based on P-III study results assessing of Ultomiris (IV qw, q8w) vs Soliris in 441 patients who were not treated with inhibitors or Soliris with patiparoxysmal […]readmore